Fig. 4. Four total serum antibody measurements individually associate with protection from sporozoite infection across RTS,S/AS01 studies.
Antibody responses were compared on the day of challenge (DOC) for the protected (P) and infected (I) groups of RTS,S/AS01 vaccinees from the Ad35.CS.01 prime (ARR, green circles), standard dose (RRR, blue triangles), and delayed fractional dose (RR_r, orange squares) regimens from two different Phase 2a studies. The top total serum antibody measurements identified were CSP (a, p = 0.003 and FDR-adjusted p = 0.034), NANP6 (b p = 0.021 and FDR-adjusted p = 0.091), NPNA3 (c, p = 0.025 and p-adjusted = 0.091), and N-interface (d, p = 0.016 and FDR-adjusted p = 0.091) specific serum antibody AUCdiss. N = 25 for MAL-068 ARR, N = 21 for MAL-068 RRR, N = 16 for MAL-071 RRR, and N = 30 for MAL-071 RR_r. Data shown for MAL-071 were previously reported and are displayed here in combination with MAL-06832. The lower and upper hinges of the boxplots correspond to the 25th and 75th percentiles, with a line at the median. The lower and upper whisker extends from the box hinges to the smallest and largest values, respectively, which are within 1.5 * IQR of the hinge (where IQR, the inter-quartile range, is equal to the distance between the 25th and 75th percentiles).